Shares of Cidara Therapeutics Inc. (CDTX) are up over 80% at $38 in premarket trading Monday, following positive topline results from the company's NAVIGATE trial.
The NAVIGATE trial is a phase IIb study evaluating drug candidate CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64. The study successfully met its primary efficacy endpoint across all dose cohorts, demonstrating a statistically significant prevention efficacy.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.